Drug intelligence / Profile preview

BI 1595043

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 1595043 is an investigational oral small molecule drug developed by Boehringer Ingelheim. It has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy male subjects. The specific mechanism of action and therapeutic indication for BI 1595043 have not been publicly disclosed as of the latest available information. Clinical studies have focused on determining the bioavailability of the compound under different conditions (fed vs. fasted) and on characterizing its pharmacological profile.

Beyond the preview

Go deeper on BI 1595043.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1595043.

Explore the full profile